INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
Publication information

Publisher & Medical Disclosure

Commercial placement

Injection Index is part of the CoreAge Rx promotional publishing network. CoreAge receives first placement and referral links may benefit this publication. Listing order is not an independently established clinical ranking.

The other brands discussed own their names and trademarks. Their inclusion does not imply endorsement of this publication. We describe public offers and do not claim to have received treatment or verified patient outcomes.

Limits of medical information

The information is general and does not establish a clinician–patient relationship. We do not diagnose, prescribe, dispense, or determine individual treatment eligibility. An online questionnaire or payment does not guarantee a prescription.

Compounded medicines are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. The clinician should explain the actual preparation and individual rationale. Clinical studies of approved products do not validate every compounded formulation.

Current agreements control purchases

Prices and terms can change after the research date. Confirm the exact preparation, supply duration, complete invoice, and cancellation rules directly. A provider purchase and its refund are governed by that provider’s agreement.

Updated October 1, 2026.

One more offer to explore

A clearly stated monthly price.

CoreAge Rx advertises compounded treatment with medication, supplies, and shipping together.

Semaglutide$99/month
Tirzepatide$149/month

No separate membership fee advertised.

Explore the CoreAge Rx plans ↗Open the full review →

A prescription and medical eligibility are required. Compounded medicines are not FDA-approved. Confirm the current offer and agreement with the provider.